Memantine, long considered to be a potential treatment for HIV-linked cognitive problems and other neurological complications, has been found not to be an effective treatment for AIDS-related dementia. However, data from the AIDS Clinical Trials Group (ACTG) study reported in the September issue of AIDS suggest that the drug may help prevent HIV damage to brain cells.
The phase II clinical trial randomized 140 patients with AIDS dementia to take either memantine (up to 40 mg a day) or placebo. Neuropsychological testing, conducted after 16 weeks, failed to find any significant improvements in either group. But the researchers also found that, using brain scans, memantine helped slow damage to brain cells, meaning that the drug may help protect against HIV-associated neuronal injury.
Memantine, approved by the FDA as Namenda in 2003, is available to treat Alzheimer’s disease. The ACTG researchers conclude that additional studies of memantine, as a possible dementia prevention and treatment option in people with HIV, should be conducted.
Beth Benne, RN, is HIV negative, but
the virus has impacted her life. She currently supervises a biannual HIV/AIDS awareness week as
the director of the student health center at Pierce College, a
community commuter school in Woodland Hills, California.
Woman of the Month is supported by exclusive advertising from Gilead.
Overheard in the Women's Forum
"I recently met a guy who is negative. I did tell him about my status and he decided to kiss me anyway (we didn't go further than that). But a day later, he called and said that he actually had a mouth ulcer that time when we kissed and he was very worried. Asked if he can get the virus from me that way. For that moment, I felt so insulted and yet I felt so bad. It was my first time having a contact with a "negative" guy."
